Safety of beta-blocker discontinuation after acute coronary syndromes with preserved or mildly reduced left ventricular ejection fraction: a target trial emulation from a real-world cohort
Beta-blocker discontinuation within 12 months following ACS with LVEF ≥40% was not associated with an increased risk of MACE compared with long-term beta-blocker therapy. Subgroup analysis suggested potential risk in STEMI patients. Discontinuing beta-blockers 12 months after ACS appears safe in patients with LVEF ≥40%, particularly after NSTEMI.
Authors
- Nicolas Rodondi (ORCID: https://orcid.org/0000-0001-9083-6896)
- David Nanchen (ORCID: https://orcid.org/0000-0002-2493-3505)
- Lorenz Räber (ORCID: https://orcid.org/0000-0003-0824-3026)
- Christian M. Matter (ORCID: https://orcid.org/0000-0002-8124-1767)
- Elena Tessitore (ORCID: https://orcid.org/0000-0003-1680-0152)
- Nicolas Johner (ORCID: https://orcid.org/0000-0001-8236-1165)
- David Carballo (ORCID: https://orcid.org/0000-0003-3212-1272)
- Stephan Windecker (ORCID: https://orcid.org/0000-0003-2653-6762)
- Stéphanie Baggio (ORCID: https://orcid.org/0000-0002-5347-5937)
- François Mach (ORCID: https://orcid.org/0000-0003-3178-9131)
- Bariş Gencer (ORCID: https://orcid.org/0000-0002-8954-9694)
- Mattia Branca
- Thomas F. Lüscher
Institutions
- University of Bern (CH)
- University of Fribourg (CH)
- University of Zurich (CH)
- University Hospital of Bern (CH)
- University Hospital of Zurich (CH)
- Centre universitaire de médecine générale et santé publique, Lausanne (CH)
- Geneva College (US)
- University of Lausanne (CH)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1093/eurjpc/zwae346
- Citations
- 6
- Primary Topic
- Cardiac, Anesthesia and Surgical Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.41
Funders
- National Science Foundation
- Reuter Foundation
- Eli Lilly and Company
- AstraZeneca
- Foundation for Cardiovascular Research
- Medtronic
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Schweizerische Herzstiftung
- Hôpitaux Universitaires de Genève
- Merck Sharp and Dohme
- Roche Diagnostics